豪杰春香

一 |     Balakrishna’s latest film Akhanda 2 released on Friday. The premieres of the devotional action entertainer (on Thursday) collected around Rs 8 crore. The numbers demonstrate Balakrishna-star power at the box office. The film opened to solid numbers on the first day (Friday) collecting Rs 22 core.          Akhanda 2 Two days box office collections     After Akhanda 2 opened to mixed response and criticism on Friday, trade pundits predicted that the Balakrishna-starrer would witness a sharp decline on the second day (Saturday). But much to everyone’s surprise, Akhanda 2 held its ground and stood firm. The Boyapati Srinu directorial managed to collect Rs 15.5 crore on day 2 despite the negativity that surrounded. This takes the overall film’s net collections to Rs 46 crore (including premieres) in India. Although the film witnessed a 30 per cent drop in collections, the decline was not as significant as predicted.                    RSS chief lauds Akhanda 2     Akhanda 2 sales on the ticketing portal BookMyShow in the last 24 hours alone stand close to 261K, demonstrating Balakrishna’s star power at the box office. With Sunday too being a holiday, the Akhanda 2 would cross the Rs 50 crore mark comfortably. In overseas too, Akhanda 2 opened to a good response. The film collected around $900K and is poised for better numbers in the weekend. Fans of Balakrishna are appreciating his performance in the action sequences and the devotional element in the story. With no big-ticket release around, makers are hoping that the film will find more love with a rise in theatrical footfalls.RSS Chief Mohan Bhagwat heaped praises on Akhanda 2. Showing appreciation for the film, he expressed hope that more films that are rooted in values would arrive in theatres in the future. Director Boyapati Srinu stated that blending traditions, spiritual themes and patriotism with a contemporary narrative style worked in their favour.Also Read: Akhanda 2 Review: An Unsubtle War Against Terror and Logic。    Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。